POAI
Price
$1.07
Change
-$0.06 (-5.26%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
9.22M
SRDX
Price
$27.97
Change
-$1.40 (-4.77%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
397.04M
50 days until earnings call
Ad is loading...

POAI vs SRDX

Header iconPOAI vs SRDX Comparison
Open Charts POAI vs SRDXBanner chart's image
Predictive Oncology
Price$1.07
Change-$0.06 (-5.26%)
Volume$1.76K
Capitalization9.22M
Surmodics
Price$27.97
Change-$1.40 (-4.77%)
Volume$1.95K
Capitalization397.04M
POAI vs SRDX Comparison Chart
Loading...
POAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
POAI vs. SRDX commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is POAI is a Hold and SRDX is a Buy.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (POAI: $1.29 vs. SRDX: $30.49)
Brand notoriety: POAI and SRDX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: POAI: 4% vs. SRDX: 76%
Market capitalization -- POAI: $9.22M vs. SRDX: $397.04M
POAI [@Medical Specialties] is valued at $9.22M. SRDX’s [@Medical Specialties] market capitalization is $397.04M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

POAI’s FA Score shows that 0 FA rating(s) are green whileSRDX’s FA Score has 0 green FA rating(s).

  • POAI’s FA Score: 0 green, 5 red.
  • SRDX’s FA Score: 0 green, 5 red.
According to our system of comparison, POAI is a better buy in the long-term than SRDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

POAI’s TA Score shows that 3 TA indicator(s) are bullish while SRDX’s TA Score has 4 bullish TA indicator(s).

  • POAI’s TA Score: 3 bullish, 6 bearish.
  • SRDX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SRDX is a better buy in the short-term than POAI.

Price Growth

POAI (@Medical Specialties) experienced а -2.27% price change this week, while SRDX (@Medical Specialties) price change was -14.21% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.19%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -4.16%.

Reported Earning Dates

POAI is expected to report earnings on May 17, 2023.

SRDX is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Medical Specialties (-2.19% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRDX($397M) has a higher market cap than POAI($9.22M). POAI YTD gains are higher at: 57.317 vs. SRDX (-23.005). SRDX has higher annual earnings (EBITDA): 22.1M vs. POAI (-13.93M). SRDX has more cash in the bank: 35.2M vs. POAI (11.9M). POAI has less debt than SRDX: POAI (3.16M) vs SRDX (33.9M). SRDX has higher revenues than POAI: SRDX (138M) vs POAI (1.81M).
POAISRDXPOAI / SRDX
Capitalization9.22M397M2%
EBITDA-13.93M22.1M-63%
Gain YTD57.317-23.005-249%
P/E RatioN/A71.51-
Revenue1.81M138M1%
Total Cash11.9M35.2M34%
Total Debt3.16M33.9M9%
FUNDAMENTALS RATINGS
POAI vs SRDX: Fundamental Ratings
POAI
SRDX
OUTLOOK RATING
1..100
809
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4679
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

POAI's Valuation (43) in the null industry is somewhat better than the same rating for SRDX (91) in the Medical Specialties industry. This means that POAI’s stock grew somewhat faster than SRDX’s over the last 12 months.

POAI's Profit vs Risk Rating (100) in the null industry is in the same range as SRDX (100) in the Medical Specialties industry. This means that POAI’s stock grew similarly to SRDX’s over the last 12 months.

POAI's SMR Rating (100) in the null industry is in the same range as SRDX (100) in the Medical Specialties industry. This means that POAI’s stock grew similarly to SRDX’s over the last 12 months.

POAI's Price Growth Rating (46) in the null industry is somewhat better than the same rating for SRDX (79) in the Medical Specialties industry. This means that POAI’s stock grew somewhat faster than SRDX’s over the last 12 months.

SRDX's P/E Growth Rating (94) in the Medical Specialties industry is in the same range as POAI (100) in the null industry. This means that SRDX’s stock grew similarly to POAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
POAISRDX
RSI
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
66%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
64%
Momentum
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 7 days ago
66%
MACD
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 7 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 7 days ago
68%
Advances
ODDS (%)
Bullish Trend 21 days ago
82%
Bullish Trend 13 days ago
70%
Declines
ODDS (%)
Bearish Trend 14 days ago
90%
Bearish Trend 7 days ago
68%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
89%
Bullish Trend 7 days ago
75%
Aroon
ODDS (%)
N/A
Bearish Trend 7 days ago
54%
View a ticker or compare two or three
Ad is loading...
POAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X87222.1950001156.515600
+1.34%
Bitcoin cryptocurrency
GME24.30-0.10
-0.41%
GameStop Corp
AAPL235.93-2.10
-0.88%
Apple
SPY576.86-6.91
-1.18%
SPDR® S&P 500® ETF Trust
TSLA272.04-12.61
-4.43%
Tesla

POAI and

Correlation & Price change

A.I.dvisor tells us that POAI and MBOT have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that POAI and MBOT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To POAI
1D Price
Change %
POAI100%
+2.38%
MBOT - POAI
33%
Poorly correlated
N/A
SINT - POAI
30%
Poorly correlated
+6.21%
APDN - POAI
28%
Poorly correlated
-7.78%
DHAI - POAI
26%
Poorly correlated
-0.84%
LFWD - POAI
25%
Poorly correlated
+0.60%
More

SRDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRDX has been loosely correlated with PXMBF. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SRDX jumps, then PXMBF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRDX
1D Price
Change %
SRDX100%
-1.49%
PXMBF - SRDX
41%
Loosely correlated
N/A
UFPT - SRDX
27%
Poorly correlated
-1.10%
ME - SRDX
27%
Poorly correlated
-6.80%
LIVN - SRDX
26%
Poorly correlated
-0.38%
PACB - SRDX
26%
Poorly correlated
+2.66%
More